AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$MRNA

Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.

Moderna's stock fell 25% on Thursday despite positive leaked data showing its cancer vaccine, developed with Merck, reduced melanoma recurrence risk by over 40% when combined with Keytruda. The vaccine also reduced cancer spread risk by 38%. Moderna's stock has risen over 500% this year on vaccine expectations. The trial focused on personalized treatment for melanoma, with experts calling it a landmark in cancer research.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 7:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging. — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MRNABearishHigh
01

Why it matters

The unexpected 25% intraday decline highlights market sensitivity to trial news and possible skepticism about commercial prospects.

02

Market read

First disclosure of pivotal trial data; despite positive efficacy, stock reaction creates immediate trading opportunity.

03

What to watch

Potential concerns about regulatory approval timeline, pricing, or manufacturing capacity not disclosed in the leak.

Relevance 8/10Novelty 8/10Timing: same-day intraday

Background

Moderna announced a breakthrough melanoma vaccine in partnership with Merck; leaked Phase 3 results show >40% risk reduction versus Keytruda alone.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna's shares plunged up to 25% after leaked positive Phase 3 data on its melanoma vaccine with Merck.

Expected impact

likely continued pressure as investors reassess valuation after unexpected drop.

Evidence & confidence

The unexpected plunge suggests market doubts about commercial rollout or pricing, creating short‑term downside risk.

$MRKNeutralMedium confidence
Context

Merck is a co‑developer of the vaccine and its immunotherapy Keytruda featured in the leaked trial data.

Expected impact

possible modest downside as investors watch the partnership impact.

Evidence & confidence

Merck's own stock is less directly affected, but the partnership news could temper sentiment.

Market effects

Sector

Biotech sector may see heightened volatility as trial data releases can trigger sharp moves regardless of outcome.

Regional

U.S. biotech equities could experience broader sell‑off in the afternoon session.

Global

Limited to markets tracking U.S. biotech stocks; no immediate global macro effect.

Counterpoint

What could challenge this read

The data is highly positive; the price drop may be an overreaction, presenting a buying opportunity.

Key entities

  • company
    Moderna

    Developer of the mRNA cancer vaccine.

  • company
    Merck

    Partner providing Keytruda immunotherapy.

Read at source← All news

StoryMerck and Moderna report positive Phase 3 melanoma vaccine results

Also covered by

6 outlets

Related articles

OCT 22
$MRKMed

Merck (MRK) Reports Promising Phase 3 Trial Results for mRNA The

Merck (MRK) reported positive Phase 3 trial results for its mRNA-based therapy intismeran autogene combined with KEYTRUDA, showing reduced risk of recurrence or death in melanoma patients. The company has a 2.41% dividend yield but a high payout ratio of 1.11, raising sustainability concerns. MRK's GF Score is 79/100, with strong profitability but weak momentum. Insiders have sold $71.4M in shares, and gurus are trimming positions. The stock is trading 22.5% above its GF Value of $121.00.

gurufocus.com3 min
OCT 22
$MRKHigh

Merck (MRK) Gains Favor as INTerpath-001 Trial Shows Promising M

Merck (MRK) gains investor attention after Phase 3 INTerpath-001 trial shows promising recurrence-free survival data for intismeran autogene in melanoma treatment. Wells Fargo maintains an Overweight rating with a $165 price target. Merck's dividend yield is 2.41%, but its payout ratio is high at 111%, raising sustainability concerns. The stock trades 22.5% above its intrinsic value of $121, indicating modest overvaluation.

gurufocus.com3 min